Biotech earnings season kicks off as Agios reports Phase 2 setback for sickle-cell drug

The second‑quarter earnings window has begun, and analysts are zeroing in on a handful of biotech companies with high‑profile catalysts.

Smaller biotechs are increasingly opting to launch their products on their own rather than partner with big pharma, intensifying competition and drawing investor attention.

Agios Pharmaceuticals disclosed that its Phase 2 trial of tebapivat in sickle‑cell disease did not meet its primary endpoints, a negative readout that will be a focal point of its earnings call scheduled for July 30.

Investors will be looking for how the company plans to leverage its remaining pipeline to offset the setback as the broader biotech sector navigates a wave of deals and regulatory clarity.